UBS raises Cardinal Health stock target to USD 295 from USD 280

Published on 10/19/2026 at 10:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cardinal Health stock costs EUR 225.00 on October 19, 2026. UBS lifted the target from USD 280.00 to USD 295.00 on October 16, 2026 and kept Buy.

Target revision and earnings date

UBS lifted its Cardinal Health target from USD 280.00 to USD 295.00 on October 16, 2026.
Fiscal 2026 revenue reached USD 254.2 billion, up 14.2 percent from fiscal 2025.
Cardinal Health stock traded at EUR 225.00 at 10:01 a.m. CEST at Lang & Schwarz on October 19, 2026.
Cardinal Health plans to report first-quarter fiscal 2027 results on November 5, 2026.

Fotorealistisches Pharma-Distributionslager mit Gabelstapler und Mitarbeitern in Dublin Ohio — Cardinal Health Inc. betreibt ein modernes Pharma-Distributionslager in Dublin, Ohio – ISIN US14149Y1082, Illustration mit AI erstellt.

Cardinal Health (ISIN US14149Y1082) received a higher UBS price target of USD 295.00, up from USD 280.00 on October 16, 2026, as Markets Insider reported. UBS retained a Buy rating, giving the analyst call a clear valuation anchor ahead of Cardinal Health's next results.

Why the target moved higher

The UBS revision followed Cardinal Health's binding letter of intent to extend its pharmaceutical distribution agreement with CVS Health through June 30, 2032. The company reaffirmed fiscal 2027 non-GAAP earnings-per-share growth of 13 percent to 15 percent, equivalent to USD 12.40 to USD 12.60, in its October 1, 2026 release from Cardinal Health. The guidance range is based on adjusted fiscal 2026 results that exclude a tariff-refund benefit.

Three dates changed the setup

On July 20, 2026, Cardinal Health agreed to acquire Strive Medical for USD 125.00 million, according to Simply Wall St. On October 1, 2026, the CVS extension and fiscal 2027 guidance reaffirmation added a continuity signal. On October 16, 2026, UBS raised its target from USD 280.00 to USD 295.00, the latest dated event.

What does the target change mean?

The valuation case rests on growth beyond the distribution base. In fiscal 2026, revenue rose 14.2 percent to USD 254.2 billion, while net income increased 9.8 percent to USD 1.7 billion, according to LineVest. The comparison shows why the higher target still depends on converting sales growth into profit after acquisition and integration costs.

Next date is November 5

Cardinal Health plans to release first-quarter fiscal 2027 results before the New York Stock Exchange opens on November 5, 2026, with its earnings discussion scheduled for 8:30 a.m. Eastern time, according to Cardinal Health.

Stock price and valuation context

Cardinal Health stock was trading at EUR 225.00 at Lang & Schwarz on October 19, 2026 at 10:01 a.m. CEST. On the NYSE, the stock closed at USD 254.06 on October 16, 2026, while its market capitalization was USD 58.8 billion and its 52-week range was USD 155.84 to USD 258.30.

The further course of trading is shown by the continuously updated real-time quote of Cardinal Health stock.